Stock listing
Intervacc Ab
Selected listing: A2DP4W · LS · EUR · DE
Intervacc Ab (Lang & Schwarz: A2DP4W), Health Technology. Latest release Jul 30, 2026: Intervacc submits Type II variation to EMA seeking 12-month duration…
- Ticker
- Lang & Schwarz: A2DP4W
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- Lang & Schwarz
- Currency
- EUR
About Intervacc Ab
The company focuses on developing innovative solutions in the field of veterinary medicine. Intervacc aims to improve animal health and welfare through its research and product offerings.
Latest news from Intervacc Ab
Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac
July 30, 2026
Intervacc completes successful evaluation of US strain of strangles pathogen ahead of clinical trials
May 22, 2026
Emil Billbäck appointed new Chair of the Board of Intervacc
May 15, 2026
Intervacc strengthens management team for future growth
May 12, 2026
Intervacc publishes the 2025 Annual Report
April 14, 2026
Research Intervacc Ab
Alternate listings
IVACC:OMXSTO
SE · SEK
Alternate listing for Intervacc Ab; the primary context on this page is A2DP4W:LS.
A2DP4W:LSX
DE · EUR
Alternate listing for Intervacc Ab; the primary context on this page is A2DP4W:LS.
2E9:FWB
DE · EUR
Alternate listing for Intervacc Ab; the primary context on this page is A2DP4W:LS.
2E9:HAM
DE · EUR
Alternate listing for Intervacc Ab; the primary context on this page is A2DP4W:LS.
2E9:SWB
DE · EUR
Alternate listing for Intervacc Ab; the primary context on this page is A2DP4W:LS.